The field of atopic dermatitis (AD) has been receiving great interest over the last few years with the approvals of both oral ...

The community screening programme charts an effective, affordable framework for TB control in the Canadian province of ...

Abbott has unveiled positive long-term data for its Esprit below-the-knee (BTK) stent in treating the most severe form of ...

Viking Therapeutics has announced its oral formulation of VK2735 has scored in a Phase I trial at ObesityWeek 2024.

Oak Hill Bio and Chiesi have enrolled the first European patient in a Phase IIb study for OHB-607, to prevent BPD in infants.

Novo Nordisk has reported positive outcomes from part one of the ESSENCE trial of semaglutide 2.4 mg in treating MASH and ...

Memo Therapeutics has completed patient enrolment for its Phase II trial of potravitug, for BK viremia (BKV) in kidney ...

The world of clinical trials is undergoing a rapid change. Today, the rise of decentralized clinical trials (DCTs) and hybrid ...

The R3 Vascular investigational device exemption will be used to launch a pivotal trial of its treatment for peripheral arterial disease.

Zai Lab has reported positive outcomes from its Phase III clinical trial of KarXT in China to treat schizophrenia.

Sutro Biopharma has begun the REFRαME-P1 trial of Luvelta to treat paediatric patients with a type of acute myeloid leukaemia (AML).

Endevica Bio has launched a new spin-off company, Abisati, to accelerate its obesity candidate into clinical trials.